Reports
Sale
Global Rheumatoid Arthritis Therapeutics Market Share, Size, Growth, Analysis; By Product Type: Biologics, Non-Biologics; By Sales Type: Prescription, Over-the-Counter (OTC), Others; By Route of Administration: Oral, Parenteral; By Distribution Channel; Regional Analysis; Supplier Landscape; Key Trends and Developments in the Market; 2023-2031
Global Rheumatoid Arthritis Therapeutics Market Outlook
The value of the global rheumatoid therapeutics market was USD 28.21 billion in 2022, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2023-2031 to reach value of USD 42.28 billion by 2031.
Key Trends in the Market
Rheumatoid arthritis or RA is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. Compared to osteoarthritis, rheumatoid arthritis could also deleteriously affect the eyes, lungs, heart, kidneys, salivary glands, and other vital organs.
- Rheumatoid arthritis therapeutics sees the involvement of Janus-Kinase inhibitors and Tumour Necrosis Factor involvement in drugs as the primary evangelists of the rheumatoid arthritis therapeutics market globally. Moreover, a plethora of drugs innovated to cater to the disease bolsters the firm hold of the market.
- Disease-modifying antirheumatic drugs (DMARDs), the primary counter-medicines to combat the disease, are maintaining a strong position in the market, despite the introduction of novel drugs.
- A surge in the obese population, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the rheumatoid arthritis therapeutics market.
- Biopharmaceuticals have been and will be one of the most substantial market drivers for the global rheumatoid arthritis market in the years to come. Biopharmaceuticals would fortify sales in the forthcoming years, having played vital roles in eradicating the disease's severity across many countries. Although the drugs are quite expensive as they are still in the market skimming period, market penetration will assuage the high prices once the firmness grows.
Global Rheumatoid Arthritis Market Analysis
Based on the product type, the market can be segmented into biologics, and non-biologics. The non-biologics segment is further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), and synthetic disease-modifying antirheumatic drugs (SDMARDs). Based on sales type, the market is bifurcated into prescription and over-the-counter (OTC).
On the basis of distribution channel, the market could be branched into hospital pharmacies, retail pharmacies, and online. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global rheumatoid arthritis therapeutics market, covering its competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
- Pfizer Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- UCB SA.
- Gilead Sciences, Inc.
- Others
Market Share by Product Type
Rheumatoid arthritis therapeutics has seen a distended disruption across the world pinned to the change in lifestyle that has exacerbated the underlying symptoms. Owing to this, medications and prophylaxis have seen a motley of options of biologics and non-biologics. Biologics have taken a significant chunk as a prophylactic alternative over the years.
Biologics have surpassed the non-biologics in the rheumatoid arthritis therapeutics market behind despite their frugal costs and budget-friendly advantage over biologics. The dominance could be ligated to the therapeutic adeptness of biologics as per various rheumatoid arthritis patients.
However, the non-biologics couldn't be wholly uprooted as it has been in the therapeutic market significantly longer than biologics. Moreover, not everyone can afford the advanced treatments of biologics; therefore, non-biologics find its user database cemented with the proletarian spectrum of the population.
Market Share by Region
Rheumatoid arthritis therapeutics have been witnessing colossal growth in North America due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the region in the rheumatoid arthritis therapeutics market. Also, the vast budget share in the arena of rheumatoid arthritis therapeutics equally raises its market share.
Europe has seen significant propellants in the form of novel drugs innovation, advanced healthcare alternatives to grapple with the disease, and an increment in the cases. In the Asia Pacific, the stanchioning infrastructure of healthcare, increasing awareness, and high adoption of biologics have catalysed the therapeutic market.
Contrary to the developing strides in North America, Europe, and Asia Pacific, the rheumatoid arthritis therapeutics market coverage hasn't matched the pace in Latin America, the Middle East, and Africa. However, growth could be anticipated after a few years on the grounds of increased awareness.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Pfizer Inc., headquartered in New York, United States, was founded in 1849. It has been instrumental in elevating the global pharmaceutical and therapeutic markets with its innovation and substantial league of drugs. The company covers a phenomenal market share across a vast gamut of therapeutics for reducing cholesterol, inflammation, and so on. It has been a major contributor to the expansion of therapeutics for rheumatoid arthritis.
Amgen Inc. is based out of California in the United States, and was founded in 1980. A leading biotechnology organisation, Amgen Inc., caters to oncology, bone health, cardiovascular disease, nephrology, neuroscience, and inflammation. The focus area of inflammation considers relevant disorders that give rise to inflammatory disorders, such as rheumatoid arthritis. It’s biologics category counters the disease and its aftermath.
Bristol-Myers Squibb Company is headquartered in New York, United States, and has been a vital contributor to the pharmaceutical and healthcare industry since its inception in 1989. The company is a merger between Bristol-Myers and Squibb and has made significant breakthroughs in neurology, haematology, cardiovascular diseases, and immunology, among others. Immunology forms the basis of the company's study and research endeavours of rheumatoid arthritis therapeutics.
Other market players include F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Sales Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Rheumatoid Arthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Rheumatoid Arthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Rheumatoid Arthritis Epidemiology (2016-2031)
5.3 Europe Rheumatoid Arthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Rheumatoid Arthritis Epidemiology (2016-2031)
5.5 Latin America Rheumatoid Arthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Rheumatoid Arthritis Epidemiology (2016-2031)
6 Global Rheumatoid Arthritis Therapeutics Market Overview
6.1 Global Rheumatoid Arthritis Therapeutics Market Historical Value (2016-2022)
6.2 Global Rheumatoid Arthritis Therapeutics Market Forecast Value (2023-2031)
7 Global Rheumatoid Arthritis Therapeutics Market Landscape
7.1 Rheumatoid Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Rheumatoid Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Rheumatoid Arthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Rheumatoid Arthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Rheumatoid Arthritis Therapeutics Market Segmentation
11.1 Global Rheumatoid Arthritis Therapeutics Market by Product Type
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Non-Biologics
11.1.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.1.3.2 Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
11.1.3.3 Others
11.2 Global Rheumatoid Arthritis Therapeutics Market by Sales Type
11.2.1 Market Overview
11.2.2 Prescription
11.2.3 Over The Counter (OTC)
11.2.4 Others
11.3 Global Rheumatoid Arthritis Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Global Rheumatoid Arthritis Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online
11.5 Global Rheumatoid Arthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals & Clinics
11.5.3 Research and Academic Laboratories
11.5.4 Others
11.6 Global Rheumatoid Arthritis Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Rheumatoid Arthritis Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Rheumatoid Arthritis Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Rheumatoid Arthritis Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Rheumatoid Arthritis Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Rheumatoid Arthritis Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Amgen Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bristol-Myers Squibb Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche Ltd
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 UCB S.A.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Gilead Sciences, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Boehringer Ingelheim GmbH
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis International AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Regeneron Pharmaceuticals, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AbbVie.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Rheumatoid Arthritis Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market size for global rheumatoid arthritis therapeutics was over USD 58.7 billion in 2022.
The projected CAGR for Rheumatoid Arthritis is around 2.70 % for the forecast period of 2023-2031.
The rise in reported cases of rheumatoid arthritis, introduction of novel drugs in the therapeutic market, and increasing awareness are the major market drivers.
A surge in the usage of biopharmaceuticals, increased accessibility of therapeutics, and breakthroughs in the domain of immunology and anti-inflammatory prophylaxis are the key trends in the market.
The key distribution channels are hospital pharmacies, retail pharmacies, and online channels.
The key players in the global rheumatoid arthritis therapeutics market are Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, UCB SA, and Gilead Sciences, Inc., among others.
Yes, rheumatoid arthritis doesn't have any permanent cure as of now. Hence, medicines must be taken consistently to mitigate the symptoms.
Rheumatoid arthritis tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER